Stem cell therapy in coronavirus disease 2019: current evidence and future potential

Shetty, Rohit; Murugeswari, Ponnalagu; Chakrabarty, Koushik; Jayadev, Chaitra; Matalia, Himanshu; Ghosh, Arkasubhra

doi:10.1016/j.jcyt.2020.11.001

Cited by 12 publications

(6 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The leading cell type was multipotent mesenchymal stromal/stem cells (MSCs) (10,(12)(13)(14), which were remarkably heterogenous in their manufacturing and clinical delivery. A pooled analysis of 24 published clinical trials on MSC infusions in COVID-19 found a relative risk reduction for all-cause COVID-19 mortality of RR=0.63 (95% CI 0.46 to 0.85), in alignment with earlier smaller summaries that suggested some clinical benefit (13,(46)(47)(48)(49)(50)(51)(52).…”

Section: Couto Et Al In a Collaboration Between Charitéberlin In Ger...supporting

confidence: 61%

Editorial: Emerging talents in alloimmunity and transplantation: 2022

Moll,

Lim,

Penack

2024

Front. Immunol.

View full text Add to dashboard Cite

Section: Couto Et Al In a Collaboration Between Charitéberlin In Ger...supporting

confidence: 61%

Editorial: Emerging talents in alloimmunity and transplantation: 2022

Moll,

Lim,

Penack

2024

Front. Immunol.

View full text Add to dashboard Cite

“…It is currently speculated that this is due to a paracrine mechanism, but this has not been confirmed. The restoration of the lung microenvironment, protection of alveolar epithelial cells, prevention of pulmonary fibrosis, and treatment of pulmonary dysfunction and lung inflammation are all possible as a result of MSC in the lung [12,13].…”

Section: Mainstream Regimens and Mechanisms Of Msc For The Treatment ...mentioning

confidence: 99%

2022 Looking Back at COVID-19 and Stem Cell Therapy

Li²,

Luo

2023

TNS

View full text Add to dashboard Cite

The global epidemic of Corona Virus Disease 2019 (COVID-19) has been raging since its outbreak in 2019, placing enormous strain on healthcare systems all over the world. The best course of action is to prevent COVID-19 in the future, despite the fact that its virological characteristics and pathogenesis have been largely understood. And all current treatment options probably include two types: one is active immunization and the other is passive immunization. Among them, passive immunity includes supportive therapy as well as neutralizing antibodies, and small molecule drugs and other treatments are used as supportive therapy, which only slows down the symptoms and prevents complications, and then waits for the body's immune system to heal itself. On the other hand, stem cell therapy is one type of active immunity. Typically, doctors use mesenchymal stem cells (MSC) to treat patients with severe or life-threatening disorders because of their potent immunomodulatory, anti-inflammatory, and tissue healing abilities. The remarkable developments in COVID-19 stem cell therapy during the past three years are outlined in this article, along with the current state of affairs. And it was found that although stem cell therapy has been successful in stages, it still has many limitations.

show abstract

“…Its applications in the treatment of various kinds of bacteria and virus infections are supported by solid experimental researches, meanwhile clinical trials are going through to further validate its safety and efficacy ( Al-Anazi and Al-Jasser, 2015 ; Marrazzo et al, 2019 ; Sleem and Saleh, 2020 ). Recently, the attention on mesenchymal stem cell (MSC) therapy rockets, with more than 50 clinical trials in progress to evaluate its application on COVID-19-associated acute respiratory distress syndrome (ARDS)/pneumonia ( Meng et al, 2020 ; Shetty et al, 2020 ). Other hot research fields include septic shock ( McIntyre et al, 2018 ; Schlosser et al, 2019 ; Laroye et al, 2020 ), human immunodeficiency virus infection ( Allam et al, 2013 ; Zhang et al, 2013 ), influenza-associated pneumonia ( Darwish et al, 2013 ), hepatitis B virus-induced liver failure/cirrhosis ( Peng et al, 2011 ; Kantarcioglu et al, 2015 ; Lin et al, 2017 ), mycobacterium tuberculosis-induced bone defects ( Zhang et al, 2021c ), and refractory cytomegalovirus infection ( Meisel et al, 2011 ).…”

Section: Microbial Disease Therapeuticsmentioning

confidence: 99%

Mesenchymal Stem Cell-Derived Exosome Therapy of Microbial Diseases: From Bench to Bed

Wu¹,

Jin²,

Ding³

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

Microbial diseases are a global health threat, leading to tremendous casualties and economic losses. The strategy to treat microbial diseases falls into two broad categories: pathogen-directed therapy (PDT) and host-directed therapy (HDT). As the typical PDT, antibiotics or antiviral drugs directly attack bacteria or viruses through discerning specific molecules. However, drug abuse could result in antimicrobial resistance and increase infectious disease morbidity. Recently, the exosome therapy, as a HDT, has attracted extensive attentions for its potential in limiting infectious complications and targeted drug delivery. Mesenchymal stem cell-derived exosomes (MSC-Exos) are the most broadly investigated. In this review, we mainly focus on the development and recent advances of the application of MSC-Exos on microbial diseases. The review starts with the difficulties and current strategies in antimicrobial treatments, followed by a comprehensive overview of exosomes in aspect of isolation, identification, contents, and applications. Then, the underlying mechanisms of the MSC-Exo therapy in microbial diseases are discussed in depth, mainly including immunomodulation, repression of excessive inflammation, and promotion of tissue regeneration. In addition, we highlight the latest progress in the clinical translation of the MSC-Exo therapy, by summarizing related clinical trials, routes of administration, and exosome modifications. This review will provide fundamental insights and future perspectives on MSC-Exo therapy in microbial diseases from bench to bedside.

show abstract

Stem cell therapy in coronavirus disease 2019: current evidence and future potential

Cited by 12 publications

References 103 publications

Editorial: Emerging talents in alloimmunity and transplantation: 2022

Editorial: Emerging talents in alloimmunity and transplantation: 2022

2022 Looking Back at COVID-19 and Stem Cell Therapy

Mesenchymal Stem Cell-Derived Exosome Therapy of Microbial Diseases: From Bench to Bed

Contact Info

Product

Resources

About